/ Nascholing /
Video’s
Toegang tot het hele platform? Registreer je vrijblijvend.
Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC (MARIPOSA-2)
Amivantamab plus lazertinib is a new standard for EGFR-mutant NSCLC (MARIPOSA-2)
The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC (MARIPOSA-2)
The clinical impact of amivantamab and chemotherapy in EGFRm NSCLC (MARIPOSA-2)
PROs for telisotuzumab vedotin in c-Met overexpressing NSCLC (LUMINOSITY)
PROs for telisotuzumab vedotin in c-Met overexpressing NSCLC (LUMINOSITY)
SOHO-02: BAY 2927088, an oral HER2 TKI, for first-line NSCLC
SOHO-02: BAY 2927088, an oral HER2 TKI, for first-line NSCLC
Emerging role of ADCs in EGFR-mutated non-small cell lung cancer
Emerging role of ADCs in EGFR-mutated non-small cell lung cancer
Durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer (ADRIATIC)
Durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer (ADRIATIC)
Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC (LAURA)
Osimertinib Improves PFS in EGFR-Mutant, Unresectable, Stage III NSCLC (LAURA)
Adagrasib versus docetaxel for previously treated KRASG12C-mutated locally advanced or metastatic NSCLC (KRYSTAL-12)
Adagrasib versus docetaxel for previously treated KRASG12C-mutated locally advanced or metastatic NSCLC (KRYSTAL-12)
CheckMate 67T: subcutaneous versus intravenous nivolumab in ccRCC (CheckMate 67T)
CheckMate 67T: subcutaneous versus intravenous nivolumab in ccRCC (CheckMate 67T)
Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC
Dr Jänne on an Exploratory Analysis from FLAURA2 of Baseline ctDNA in EGFR+ NSCLC
ESMO 2023 Adjuvant alectinib leidt tot langere DFS bij ALK+ NSCLC
ESMO 2023 Adjuvant alectinib leidt tot langere DFS bij ALK+ NSCLC
ESMO 2023 Eerstelijns selpercatinib effectiever dan pembrolizumab-chemotherapie bij RET-positief NSCLC
ESMO 2023 Eerstelijns selpercatinib effectiever dan pembrolizumab-chemotherapie bij RET-positief NSCLC
ESMO 2023 Combinaties met amivantamab effectiever dan chemotherapie bij NSCLC met gemuteerd EGFR
ESMO 2023 Combinaties met amivantamab effectiever dan chemotherapie bij NSCLC met gemuteerd EGFR
ESMO 2023 Datopotamab deruxtecan bij gevorderd NSCLC
ESMO 2023 Datopotamab deruxtecan bij gevorderd NSCLC
CheckMate 9LA studie – korte uitleg
CheckMate 9LA studie – korte uitleg
ESMO 2022 – Highlights IPSOS study
